Evidence map›Paper›PMID 20729304›Full record

ArticleJournal of leukocyte biology2010

Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.

Chung Hee Sonn, Young-Bin Yu, Young-Joo Hong, Young-Jun Shim, Jeffrey A Bluestone, Bon-Hong Min, Kyung-Mi Lee

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Chung Hee SonnKorea University College of Medicine, 126-1 Anam-dong 5-ga, Seongbuk-gu, Seoul, Korea.
Young-Bin Yu
Young-Joo Hong
Young-Jun Shim
Jeffrey A Bluestone
Bon-Hong Min
Kyung-Mi Lee
Korea University · KRUniversity of California, San Francisco · US

Funding

IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MABR01AI046643 · NIAID · UNIVERSITY OF CHICAGO · PI BLUESTONE, JEFFREY A · 2000 to 2015
$1.8M
NIAID NIH HHS R01 AI046643
6 · The paper itself

Abstract

CLU is a secreted, multifunctional protein implicated in several immunologic and pathologic conditions. As the level of serum CLU was shown to be elevated during inflammatory responses, we questioned if CLU might interact with circulating lymphocytes leading to functional consequences. To assess this possibility directly, mouse splenocytes and purified NK cells were cultured with varying dose of CLU, and its effect on cell proliferation was examined. Our data showed that CLU up-regulated DNA synthesis and expansion of NK cells significantly in response to a suboptimal, but not maximal, dose of IL-2, and CLU alone did not exhibit such effects. This CLU-mediated synergy required the co-presence of CLU at the onset of IL-2 stimulation and needed a continuous presence during the rest of the culture. Importantly, NK cells stimulated with CLU showed increased formation of cell clusters and a CD69 activation receptor, representing a higher cellular activation status compared with those from the control group. Furthermore, these NK cells displayed elevated IFN-γ production upon RMA/S tumor target exposures, implying that CLU regulates not only NK cell expansion but also effector function of NK cells. Collectively, our data present a previously unrecognized function of CLU as a novel regulator of NK cells via providing costimulation required for cell proliferation and IFN-γ secretion. Therefore, the role of CLU on NK cells should be taken into consideration for the previously observed, diverse functions of CLU in chronic inflammatory and autoimmune conditions.

Indexed as

AnimalsBlotting, WesternCell DivisionClusterinDose-Response Relationship, DrugDrug SynergismFlow CytometryHumansInterferon-gammaInterleukin-2Killer Cells, NaturalMiceSpleenClusterinInterferon-gammaInterleukin-2

Identifiers

PMID20729304
PMCPMC6608014
OpenAlexW2136378760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.